simcere pharmaceutical group
Simcere Pharma To Sell Equity Stake In Bodapharmaceutical
Simcere Pharma has sold its stake in Jilin Bodapharmaceutical Co., Ltd. to Zhuhai Rongding Equity Investment Partnership L.P.
BMS, Simcere Pharma To Co-Develop Orencia® SC In China
BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia® for the treatment of rheumatoid arthritis in China.
Simcere To Begin Clinical Trials On VEGF Inhibitor
Simcere Pharma has received SFDA approval to begin first-in-man trials with its humanized monoclonal antibody candidate, APX003.
Simcere Pharma & BMS To Develop CETP Inhibitor BMS-795311
BMS and Simcere Pharma have agreed to co-develop BMS-795311, a preclinical small molecule inhibitor of the cholesteryl ester transfer protein.
Simcere Receives CFDA Approval For Anti-Rheumatic Drug Iremod
The State Food and Drug Administration has approved Simcere Pharmaceutical Group's new anti-rheumatic drug, Iremod, used to treat symptoms of active rheumatic arthritis.
Merck And Simcere Pharma Establish Chinese Joint Venture
Merck and China's Simcere Pharmaceutical Group announced on Thursday a framework agreement to establish a joint venture in China.
